SGO 2026 Preview: Evolving Standards in Cervical Cancer Screening, Prevention, and Treatment
According to the American Cancer Society (ACS), in 2026, an estimated 13,490 new cases of invasive cervical cancer will be diagnosed, and an estimated 4,200 women will die from cervical cancer.
The article discusses the current epidemiology of cervical cancer, recent advances in screening and prevention—including HPV self‑collection and vaccination—, emerging therapeutic options such as pembrolizumab in chemoradiation and tisotumab vedotin, and updates to national screening guidelines for 2026, all aimed at reducing incidence and mortality.
The figures highlight the ongoing public‑health impact of cervical cancer and underscore the importance of enhanced screening, vaccination, and novel therapies to improve outcomes.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- A multinational cross-sectional study on human papillomavirus and cervical cancer knowledge, vaccination attitudes, and risk factors in the Middle East
- Genomic features of cervical cancer
- Screening for Cervical Cancer
- Cervical cancer: Epidemiology, risk factors and screening
- AI approach outperformed human experts in identifying cervical precancer